Anti-Ro52 antibodies in idiopathic inflammatory myopathies: clinical significance across myositis-specific antibody-defined subgroups
Clicks: 2
ID: 326514
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
0.3
/100
2 views
1 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #189 of 202 articles by views in Lara D. Veeken
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 202 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Objective To investigate the frequency, clinical characteristics, and prognostic value of anti-Ro52 antibodies in patients with idiopathic inflammatory myopathies (IIMs), especially in IIM subgroups with distinct myositis-specific antibodies (MSAs). Methods This cohort included 2,126 patients with IIMs treated at the China-Japan Friendship Hospital between April 2002 and April 2023. Associations between clinical features and outcomes with anti-Ro52 antibodies were evaluated in each MSA-defined subgroup. Results In total, 978 (46.0%) patients presented with anti-Ro52 antibody positivity. Anti-Ro52 antibodies represented the most common myositis-associated antibody in IIM patients, with notably higher frequencies observed in patients with anti-MDA5+ dermatomyositis (DM) and anti-synthetase syndrome (ASyS) compared to other IIM serotypes. In patients with anti-MDA5+ DM, anti-Ro52 antibodies were associated with interstitial lung disease (ILD), rapidly progressive ILD, and worse prognosis. Coexistence of anti-Ro52 and anti-SSA antibodies was further associated with a worse prognosis in anti-MDA5+ DM. In ASyS, anti-Ro52 antibodies were associated with pulmonary involvement but not with prognosis. In other MSA-defined subgroups, the clinical significance of anti-Ro52 antibodies was limited. Conclusion Anti-Ro52 antibodies are highly prevalent in patients with IIMs, especially those with anti-MDA5+ DM and ASyS. Anti-Ro52 antibody testing may be a valuable tool for risk stratification and prognostic assessment in anti-MDA5+ DM and ASyS.
| Reference Key |
openalex_W7204238411
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Qi Pan, Shuai Li, Xinyue Guo, Shanshan Li, Yiran Chen, Huihui Ji, Xiaoqin Luo, Yunfeng Dai, Longyang Zhu, Chen Zong, Lin Luo, Ying Li, Xinxin Zhang, Xiaoming Shu, Xin Lu, Guochun Wang, Qinglin Peng |
| Journal | Lara D. Veeken |
| Year | 2026 |
| DOI |
10.1093/rheumatology/keag462
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.